Vertex Pharmaceuticals expanded the company’s collaborative partnership with CRISPR Therapeutics to develop and commercialize a possible cure for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The focus is on the development of CTX001, an autologous, ex vivo CRISPR-CAS9 gene-edited therapy.
Dentsu International announced on April 20 the launch of dentsu health, a global solution. Drawing upon the expertise of dentsu’s global network of 2,000 health marketing experts across 85 markets in EMEA, APAC and the Americas, dentsu health is poised to become one of the top global healthcare agencies.
Havas Health & You announced that HH&Y is the first health network to become a Global Content Partner as part of Veeva Systems’ Content Partner Program.
The U.S. State Department will boost its “Do Not Travel” guidance to about 80 percent of countries worldwide, citing “unprecedented risk to travelers” from the Covid-19 pandemic.
Face2Face America, a nationwide, community-driven Covid-19 vaccine education initiative, launched a call to action to engage other members of the healthcare communications industry to lend support to their initiative to fight vaccine hesitancy.
Drugmakers Johnson & Johnson, Endo International, AbbVie’s Allergan unit, and Teva Pharmaceutical headed to court on April 19 in California over claims the companies engaged in deceptive marketing practices that fueled the opioid crisis in America.
CVS Health Corp. said on April 19 it will offer three over-the-counter Covid-19 tests at drugstores as well as online, expanding access to home testing in the United States.
Florence Healthcare’s Senior Implementation Manager Amanda Korey presents a roadmap that not only fosters collaboration between sites, sponsors and CROs, but also results in robust user adoption across all stakeholder groups.
Four drugmakers, including Johnson & Johnson and Teva Pharmaceutical Industries Ltd., will go to trial on April 19 over claims they helped fuel an opioid crisis that has resulted in nearly 500,000 overdose deaths in the United States.
In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.
